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Human pluripotent stem cells (hPSCs) are a promising cell source for regenerative medicine, but their
derivatives need to be rigorously evaluated for residual stem cells to prevent teratoma formation. Here,
we report the development of novel surface-enhanced Raman scattering (SERS)-based assays that can
detect trace numbers of undifferentiated hPSCs in mixed cell populations in a highly speciﬁc, ultra-
sensitive, and time-efﬁcient manner. By targeting stem cell surface markers SSEA-5 and TRA-1-60
individually or simultaneously, these SERS assays were able to identify as few as 1 stem cell in
106 cells, a sensitivity (0.0001%) which was ~2000 to 15,000-fold higher than that of ﬂow cytometry
assays. Using the SERS assay, we demonstrate that the aggregation of hPSC-based cardiomyocyte dif-
ferentiation cultures into 3D spheres signiﬁcantly reduced SSEA-5þ and TRA-1-60þ cells compared with
parallel 2D cultures. Thus, SERS may provide a powerful new technology for quality control of hPSC-
derived products for preclinical and clinical applications.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Owing to their distinct self-renewal and differentiation prop-
erties, human pluripotent stem cells (hPSCs), either human em-
bryonic stem cells (hESCs) or human induced pluripotent stem cells
(iPSCs), hold great potential as a cell source for regenerative med-
icine. However, these properties also make them potentially
tumorigenicdeven a small number of undifferentiated hPSCs are
sufﬁcient to generate teratomas when transplanted in vivo [1,2].
Hence, the risk of tumorigenesis is a major concern for the clinical
translation of all hPSC-derived products [3]. Animal studies doc-
umenting the risk of teratoma formation following transplantation
of hPSC-derivatives have spurred efforts to evaluate and enhanceof Medicine, 2015 Uppergate
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Ltd. This is an open access article uthe safety of hPSC-based therapies [4e10]. For clinical safety, a
highly sensitive and speciﬁc quality control assay is required to
determine the number of undifferentiated cells in hPSC-derived
products.
In current practice, cell-based assays such as ﬂow cytometry can
detect undifferentiated cells when present at ~0.1% or higher in a
mixed cell population [11], which is insufﬁcient sensitivity to
ascertain that a cell preparation for transplantation contains a
number of hPSCs below the threshold for teratoma formation. A
study in mice reported that 104 undifferentiated cells were sufﬁ-
cient to produce tumors in vivo [2]. Accordingly, if an estimated
109 cells are required for a single transplantation for heart failure
[12], the sensitivity of assays used to detect residual undifferenti-
ated cells needs to be 1 stem cell in a background of 105 cells
(0.001%), which is unachievable via ﬂow cytometry.
A prevailing method to evaluate the risk of teratoma formation
is to inject cell products into SCID mice and evaluate tumor for-
mation after at least 3 months [3,13e15]. While this method may
provide a direct assessment of tumorigenicity, it is highly imprac-
tical as a quality-control assay due to its non-quantitative, non-nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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that is fast, highly sensitive, and efﬁcient in detecting a trace
number of undifferentiated cells is imperative for assessing the
safety of hPSC-derived products.
Nanoparticle-based surface-enhanced Raman scattering (SERS)
technology is gaining momentum in biomedical applications such
as molecular multiplex detection, pathogen and cell detection, and
in situ imaging [16e21]. When conjugated with biomolecular tar-
geting ligands, Raman reporter-labelled gold (Au) nanoparticles can
be used to detect speciﬁc molecules with high speciﬁcity and
sensitivity [19,21e23]. SERS detection produces a sharp,
ﬁngerprint-like spectral pattern that is distinct from other inter-
ference patterns in a complex biological environment. This is
uniquely advantageous when detecting a low number of cells, since
conventional ﬂuorescence signals may be masked by the scattering
signals of background cells [20,21]. In this study, we developed
SERS-based assays targeting the hPSC surface markers stage-
speciﬁc embryonic antigen-5 (SSEA-5) and TRA-1-60 to detect re-
sidual undifferentiated hPSCs with high speciﬁcity and sensitivity.
Using our newly developed assays, we efﬁciently detected SSEA-5þ
and TRA-1-60þ cells at sensitivities several orders of magnitude
higher than ﬂow cytometry assays. As such, these assays represent
a rapid, efﬁcient, and economic method for assessing the safety of
hPSC-based products for pre-clinical and clinical applications.
2. Materials and methods
2.1. Materials
Ultrapure water (18 MU cm1) was used to prepare all aqueous
solutions. The following chemicals were used without further pu-
riﬁcation: 60 nm citrate-stabilized gold nanoparticles (2.6  1010
particles/mL) (Ted Pella Inc.), black hole quencher (BHQ) (Biosearch
Technologies), PEG-SH (MW ¼ 5,000 and 20,000 Da) (Rapp Poly-
mere, Germany), SSEA-5 IgG1 antibody (Stemcell Technologies),
and TRA-1-60 IgM antibody (Millipore). All other reagents were
obtained from Sigma-Aldrich at the highest purity available.
2.2. BIDI reporter molecule
The molecular structure of (E)-2-(2-(5'-(dimethylamino)-[2,2'-
bithiophen]-5-yl)vinyl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium
iodide (BIDI) is shown here. The synthesis of BIDI will be reported
later in another work.BIDI 1HNMR (DMSO, 500 MHz): d ¼ 8.61e8.64 (d, 1H, C10H6),
8.36e8.38 (d, 1H, C10H6), 8.21e8.23 (d, 1H, C2H2), 8.15e8.17 (d, 1H,
C10H6), 8.04e8.05 (d, 1H, C4H2S), 7.97e7.99(1, H, C2H2), 7.74e7.77
(m, 1H, C10H6), 7.63e7.66 (m, 1H, C10H6), 7.56e7.57 (d, 1H, C4H2S),
7.37e7.38 (d, 1H, C4H2S), 6.84e6.87 (d, 1H, C10H6), 6.16e6.17 (d, 1H,
C4H2S), 4.05 (s, 3H, CH3), 3.08 (s, 6H, CH3), 1.98 (s, 6H, CH3).MALDI-
TOF-MS: m/z433.0 (M-I-).2.3. Preparation of SSEA-5-conjugated and TRA-1-60-conjugated
nanoparticles
Au nanoparticles were labelled with Raman reporters as
described previously [24], conjugatedwith SSEA-5 (IgG1) or TRA-1-
60 (IgM) antibodies, and then coated with polyethylene-glycol
(PEG). Amine function group of TRA-1-60 IgM antibody was
modiﬁed to couple with a streptavidin linker for 3 h at room
temperature. Excess glycine was used to quench the un-reacted
linker. The bioconjugation of SSEA-5 or TRA-1-60 antibodies with
nanoparticles was carried out using previously reported procedures
[24]. Brieﬂy, the 60 nm citrate-stabilized Au nanoparticles were
labelled with BHQ reporter molecules via adsorption to the nega-
tively charged Au nanoparticle surface through electrostatic
interaction.
To prepare Au nanoparticles conjugated with SSEA-5 or TRA-1-
60 antibodies, Au-BHQ nanoparticles ﬁrst were reacted with
varying quantities of antibodies (10, 25, 50, 100, 200 antibodies/
ligands per particle). The reaction was performed at room tem-
perature with shaking for 2 h and the mixture was incubated at
4 C overnight. Complete PEGylation of the unreacted gold surface
required the introduction of excess 10 mM PEG-SH into the reaction
mixture and was performed at room temperature with shaking for
1 h. The reaction mixture was centrifuged at 4000  g for 20 min,
followed by removal of the supernatant fraction that contained
unreacted antibodies and PEG-SH. Antibody-conjugated nano-
particles formed a pellet at the bottom of the reaction vial. The
pellet was washed three times with 1 mL of 1  PBS and repetitive
centrifugation. The ﬁnal concentration of the bio-conjugated Au
nanoparticles was determined by the measurement of UVeVis
absorption spectrum using a Raman detection system. For the
multiplexing assay, SSEA-5 antibodies were conjugated with Au
nanoparticles labelled with the BIDI reporter and TRA-1-60 anti-
bodies with Au nanoparticles labelled with the BHQ reporter.
Antibody-conjugated nanoparticles were characterized as
described previously [24] with minor modiﬁcation. UVeVis ab-
sorption spectra were recorded on a Shimadzu (UV-2401) spec-
trometer using disposable polyacryl cuvettes. Transmission
electronmicrographs (TEM)were takenwith a Hitachi H7500 high-
magniﬁcation electron microscope. For the preparation of samples
for TEM, nanoparticle samples (5 mL each) were dropped onto
copper 200 mesh grids that were pre-treated with UV light to
reduce static electricity. After 30 min, the solvent was drained with
a ﬁlter paper.
SERS spectra were recorded on a compact Raman system (Si-
erra, Snowy Range Instruments) using 785 nm (70 mW) excitation.
The scanning laser beam has a footprint of 1.7 mm diameter with
25 mm focal size. SERS intensities were normalized to the Raman
spectra of cyclohexane and polystyrene to correct for variations in
optical alignment and instrument response. The spectral resolution
was approximately 4 cm1. Typical spectrum acquisition time is
1 s.2.4. Cell culture
Human induced pluripotent stem cells (IMR-90 iPSCs, WiCell-
Research Institute) and human embryonic stem cells (H7 hESCs
[25], NIH registration no. 0061) were maintained in Essential 8™
(E8) medium (Life Technologies) on growth factor-reduced Matri-
gel™ (1:60, v/v, Fisher Scientiﬁc Inc.). NIH3T3 ﬁbroblasts were
maintained in DMEM medium supplemented with 10% FBS. Pri-
mary rat cardiomyocytes were isolated as described previously
[26]. All cultures were under standard culture conditions (5% CO2,
37 C).
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nanoparticles
For the evaluation of the speciﬁcity of SSEA-5-conjugated and
TRA-1-60-conjugated nanoparticles, 500,000 cells were prepared
for each cell type (IMR-90 iPSCs, H7 hESCs, primary rat car-
diomyocytes and NIH3T3 ﬁbroblasts). These samples were ﬁxed
with 2% paraformaldehyde (PFA) pretreated with an endogenous
biotin-blocking reagent (cat No. E-21390, Life Technologies) and
then incubatedwith 5 pMSSEA-5-conjugated nanoparticles or TRA-
1-60-conjugated nanoparticles in 2% BSA for 30 min at room tem-
perature, followed by three washes with PBS containing 0.1% BSA
and 0.1% Tween® 20 (PBST). The cells were centrifuged and the
entire cell pellet was analyzed using a Raman system for each
ensemble measurement (Excitation wavelength: 785 nm; laser
power: 70 mW; integration time: 1 s) [27].
For the evaluation of the speciﬁcity of SSEA-5-conjugated and
TRA-1-60-conjugated nanoparticles in multiplex labeling,
500,000 cells were prepared for each cell type (IMR-90 iPSCs, H7
hESCs, primary rat cardiomyocytes and NIH3T3 ﬁbroblasts). Upon
blocking endogenous biotin, samples were incubated with 5 pM
SSEA-5-conjugated nanoparticles and 5 pM TRA-1-60-conjugated
nanoparticles. The SERS spectra from each sample were measured
using a Raman system (785 nm laser excitation) and analyzed as
described [27].2.6. Sensitivity of SSEA-5-conjugated and TRA-1-60-conjugated
nanoparticles
For the determination of the sensitivity of SSEA-5-conjugated
and TRA-1-60-conjugated nanoparticles, samples containing
varying numbers of stem cells were prepared by mixing hPSCs
(IMR-90 iPSCs or H7 hESCs) with 1  106 NIH3T3 ﬁbroblasts. Final
cell preparations contained 1  106 NIH3T3 ﬁbroblasts mixed with
0, 10, 50, 500, 1000, 10,000, 100,000 hPSCs (3 replicates each).
Following ﬁxation with 2% PFA and a treatment with the endoge-
nous biotin-blocking reagent, these samples were incubated with
2.5 pM SSEA-5-conjugated nanoparticles or TRA-1-60-conjugated
nanoparticles for 30 min. After washing 3 times, the SERS spectra
of each sample were measured in cell pellets of 10 uL with 785 nm
laser excitation using a compact Raman system (Sierra, Snowy
Range Instruments). The limit of detection LOD was deﬁned as the
lowest concentration of stem cells that can be distinguished from
background cell populations without stem cells (e. g., NIH3T3 cells).
For the determination of the LOD for each assay, the mean of SERS
intensity (y-axis) was plotted against the concentration of stem
cells (x-axis). A linear standard curve was then drawn between the
SERS intensity and the concentration of stem cells. Next, a hori-
zontal line was drawn at the SERS intensity value that equals to the
mean plus 3 standard deviations of the measurements of NIH3T3
cells. The LOD was then determined as the concentration of stem
cells at the intersection between the horizontal line and the stan-
dard curve.
Determination of the sensitivity of the multiplexing assays was
performed similarly using cell preparations containing various
numbers of stem cells. These cells were then co-incubated with
both 2.5 pM SSEA-5-conjugated nanoparticles and 2.5 pM TRA-1-
60-conjugated nanoparticles followed by the measurement and
analysis of the SERS spectra. SERS signals were examined and
plotted as standard curves based on their ﬁngerprint signatures of
SERS spectra contributed by SSEA-5-conjugated and TRA-1-60-
conjugated nanoparticles, respectively. The LOD was then deter-
mined as aforementioned for single marker detection.2.7. In vitro cardiomyocyte differentiation
Directed cardiomyocyte differentiation was achieved by a serial
application of growth factors, activin A and BMP4 as described
previously [28]. Brieﬂy, conﬂuent undifferentiated IMR-90 iPSCs
were treated with 100 ng/mL activin A for a day and then BMP4 for
4 days in serum-free Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with insulin-free B27 (day 0). After 24 h
treatment, the cultures were treated with 10 ng/mL BMP4 in RPMI/
insulin-free B27medium for 4 days. After differentiation day 5, cells
were maintained in the serum-free medium RPMI/B27 containing
insulin, and medium was replenished every other day. To initiate
3D sphere culture, cells at differentiation day 4 were dissociated
and forced to form cell aggregates in microwell plates as described
previously [28]. The spheres were transferred to suspension culture
and maintained in low-attachment plates.
2.8. Flow cytometry
For ﬂow cytometry analysis of SSEA-5þ and TRA-1-60þ cells,
samples were stained using 1:100 mouse monoclonal SSEA-5 IgG1
(Stemcell Technologies, 60063) and/or 1:200 mouse monoclonal
TRA-1-60 IgM (Millipore, MAB4360) for 30 min at room tempera-
ture [29]. Isotype controls used were mouse IgG1 (BD Biosciences,
554121) and mouse IgM (BD Biosciences, 557275). Secondary
antibody staining was performed with 1:1000 Alexa Fluor® 488
goat anti-mouse IgG1 (Life Technologies) and/or Alexa Fluor® 594
goat anti-mouse IgM (Life Technologies) for 25 min at room tem-
perature. Cardiomyocyte purity was analyzed by ﬂow cytometry
analysis of a-actinin, a cardiomyocyte-associated marker, as
described previously [30]. Samples were analyzed using a FACS
LSRII ﬂow cytometer (BD Biosciences) and FACSDiva software. At
least 2  104 events were recorded and data were analyzed using
FlowJo (TreeStar).
2.9. Detection of SSEA-5þ and TRA-1-60þ stem cells in
differentiation cultures by SERS assay
Test samples from differentiation cultures and standard samples
(cell preparations containing various numbers of hPSCs mixed with
NIH3T3 ﬁbroblasts) were ﬁxed with 2% PFA and pretreated with the
endogenous biotin-blocking reagent and incubated with SSEA-5-
conjugated and TRA-1-60-conjugated nanoparticles with distinct
Raman spectral patterns as described in section 2.5 for the multi-
plexing assay. Upon a thrice washing, cells were recorded for SERS
spectra, and SERS signals from SSEA-5-conjugated and TRA-1-60-
conjugated nanoparticles were analyzed by their unique SERS
spectrum ﬁngerprints. Linear standard curves were constructed
from standard samples: the intensities of SERS signals from SSEA-
5-conjugated and TRA-1-60-conjugated nanoparticles were plotted
against the concentrations of stem cells. Levels of residual SSEA-5þ
and TRA-1-60þ cells in the test samples were determined according
to the standard curves. Data are presented as mean ± standard
deviation of 3 measurements.
3. Results
3.1. Optimization of SSEA-5-conjugated and TRA-1-60-conjugated
nanoparticles
In order to speciﬁcally detect residual stem cells, we developed
two SERS assays by functionalizing Au nanoparticles with anti-
bodies targeting stem cell surface markers, SSEA-5 and TRA-1-60.
Both markers are speciﬁc to pluripotent stem cells and could be
used to delineate undifferentiated cells from differentiated cells
Fig. 1. Schematic of the SERS assay principle and design of SSEA-5-conjugated and TRA-1-60-conjugated nanoparticles. (A) The assay principle using SSEA-5-conjugated and/or
TRA-1-60-conjugated nanoparticles to detect pluripotent stem cells. Cells were incubated with SSEA-5- and/or TRA-1-60-conjugated nanoparticles. After washing, SERS signals
from cell pellets were detected by laser and SERS spectra were analyzed. (B) Schematic diagram showing the preparation of Raman-encoded, PEG-stabilized, and SSEA-5-
functionalized Au nanoparticles. (C) Preparation of Raman-encoded, PEG-stabilized, and TRA-1-60-functionalized Au nanoparticles.
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detecting rare stem cells. Upon staining and washing steps, the
level of stem cells bonded with nanoparticles was detected by a
Raman detection system.
SSEA-5 (IgG1)-conjugated and TRA-1-60 (IgM)-conjugated
nanoparticles were prepared through several steps including
Raman encoding, antibody conjugation, and polyethylene-glycol
(PEG) stabilization (Fig. 1B and C). As examined by transmission
electron microscopy (TEM), the nanoparticles had a relative uni-
form sizewith a diameter of ~60 nm (Supplementary Fig.1A). These
nanoparticles had optical absorption peaked at awavelength of 524
nm, a typical proﬁle for Au nanoparticles (Supplementary Fig. 1B).
The number of reporter molecules per Au nanoparticle was opti-
mized and carefully titrated to achieve maximal SERS signals and
minimal colloid aggregation. A ratio of ~12,000 Raman reporter
molecules per nanoparticle produced the highest SERS intensity
with minimal colloid aggregation and therefore was used
throughout the experiments (Supplementary Fig. 1).
We optimized the nanoparticles in order to obtain high relative
SERS signal ratio, i.e., the SERS signal ratio of positive cells (hPSCs)
vs. negative cells (NIH3T3 cells). Due to signiﬁcant differences in
the size and structure of SSEA-5 (IgG1) and TRA-1-60 (IgM) anti-
bodies, we applied a two-step approach to optimize the antibody-
conjugated nanoparticles by ﬁrst modifying the PEG stabilizing
layer and then titrating the ligand density. In the ﬁrst step, we
evaluated the effect of the length of PEG layers on relative SERS
signal ratios of IMR-90 iPSCs (positive cells) and NIH3T3 ﬁbroblasts
(negative cells). For TRA-1-60 (IgM)-conjugated nanoparticles, wehypothesized that the length of the PEG-SH needs to be increased
to reduce the non-speciﬁc binding from IgM (Fig. 2A). As expected,
we observed high background signal from NIH3T3 ﬁbroblasts using
TRA-1-60-conjugated nanoparticles prepared with PEG-SH with
molecular weight of 5000 Da (PEG5K) as protective layer (Fig. 2B,
dark blue spectra), indicating PEG5K was not sufﬁcient to prevent
non-speciﬁc binding of the large pentamer structure of IgM. In
contrast, nanoparticles stabilized with PEG-SH with molecular
weight of 20,000 Da (PEG20K) gave negligible SERS signals for non-
stem cells (Fig. 2B, pink spectra) and generated the highest relative
SERS signal ratio of hPSCs vs. NIH3T3 ﬁbroblasts at ~130, which was
~26-fold higher comparedwith those detected by the nanoparticles
coated with PEG5K (Fig. 2C).
In the second step, we examined the effect of antibody/ligand
density on the relative SERS signals. It has been well documented
that the binding afﬁnity of nanoparticles increases with higher
ligand density [32]; however, too many ligands per particle could
also cause higher non-speciﬁc binding due to higher charge and
more exposed hydrophobic pockets. Therefore, optimizing ligand
density per particle is one of the critical steps to achieve high
speciﬁcity of the assay. To this end, we prepared nanoparticles with
various ligand densities and compared the relative SERS signals of
these nanoparticles. The highest relative SERS signal ratio of hPSCs
vs. NIH3T3 ﬁbroblasts was observed when the nanoparticles were
prepared with a ligand density of 25 SSEA-5 antibodies per particle
(Fig. 3A) and 100 TRA-1-60 antibodies per particle (Fig. 3B),
respectively. Thus, these ligand densities were selected for the
preparation of nanoparticles in further experiments.
Fig. 2. Effect of the PEG-SH layer of TRA-1-60-conjugated nanoparticles on relative SERS signals. (A) Schematic of applying PEG-SH layers with a molecular weight of 5000 Da
(PEG5K) or 20,000 Da (PEG20K) onto TRA-1-60-conjugated nanoparticles. (B) SERS signals from PEG20K- and PEG5K-stabilized nanoparticles in IMR-90 iPSCs or NIH3T3 ﬁbroblasts
(3T3). Note: PEG20K-stabilized nanoparticles produced negligible SERS signals from NIH3T3 ﬁbroblasts (pink spectra), while PEG5K-stabilized nanoparticles produced high
background signals from NIH3T3 ﬁbroblasts (dark blue spectra). (C) The relative SERS signals from PEG20K-stabilized and PEG5K-stabilized nanoparticles targeting IMR-90 iPSCs vs.
NIH3T3 ﬁbroblasts. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Effect of antibody/ligand density on relative SERS signals. Nanoparticles were conjugated with various amounts of antibodies and compared for their relative SERS signals
targeting IMR-90 iPSCs vs. NIH3T3 ﬁbroblasts. (A) Effect of the ligand density on the relative SERS signals from SSEA-5-conjugated nanoparticles targeting IMR-90 iPSCs vs. NIH3T3
ﬁbroblasts. Note: A ligand density of 25 ligands per particle in SSEA-5-conjugated nanoparticles produced the highest signal ratio. (B) Effect of the ligand density on the relative
SERS signals from TRA-1-60-conjugated nanoparticles targeting IMR-90 iPSCs vs. NIH3T3 ﬁbroblasts. Note: A ligand density of 100 ligands per particle in TRA-1-60-conjugated
nanoparticles produced the highest signal ratio.
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Fig. 4. Speciﬁcity of SSEA-5-conjugated and TRA-1-60-conjugated nanoparticles for the detection of hPSCs. (A) Cells (500,000 cells/test) were pretreated with an endogenous
biotin-blocking reagent and then incubated with nanoparticles for 30 min. Following washing, the cells were centrifuged and the cell pellet was analyzed using a Raman system for
each ensemble measurement. Excitation wavelength: 785 nm; laser power: 70 mW; integration time: 1 s. Note: SERS signals from SSEA-5-conjugated and TRA-1-60-conjugated
nanoparticles were detected in pluripotent stem cells, IMR-90 iPSCs (red) and H7 hESCs (black), but not in non-stem cells, primary rat cardiomyocytes (CM, blue) or NIH3T3 ﬁ-
broblasts (3T3, green). (B) Flow cytometry analysis of pluripotent stem cell surface markers. SSEA-5þ cells and TRA-1-60þ cells were detected in IMR-90 iPSCs and H7 hESCs, but not
in cardiomyocytes or NIH3T3 ﬁbroblasts. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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markers: speciﬁcity and sensitivity
We next assessed the speciﬁcity of SSEA-5-conjugated and TRA-
1-60-conjugated nanoparticles using cells with (IMR-90 iPSCs and
H7 hESCs) or without (primary cardiomyocytes and NIH3T3 ﬁbro-
blasts) these speciﬁc surface markers. After cells were incubated
with SSEA-5-conjugated nanoparticles or TRA-1-60-conjugated
nanoparticles, strong SERS signals were detected only in pluripo-
tent stem cells with these surface markers (Fig. 4A), suggesting
speciﬁc bindings of these two nanoparticles to pluripotent stem
cells. Nanoparticles conjugated with corresponding isotype con-
trols (IgG1 or IgM) also displayed negligible SERS signals for all cell
lines (data not shown). As expected, ﬂow cytometry analysis indi-
cated that SSEA-5 and TRA-1-60 were speciﬁcally expressed onIMR-90 iPSCs and H7 hESCs, but not on cardiomyocytes or ﬁbro-
blasts (Fig. 4B). Therefore, both SSEA-5-conjugated and TRA-1-60-
conjugated nanoparticles speciﬁcally detected pluripotent stem
cells.
To determine the sensitivity of these SERS assays, we ﬁrst
generated cell preparations containing various amounts of hPSCs
bymixing hPSCs with NIH3T3 ﬁbroblasts. Each cell preparationwas
then analyzed with SSEA-5-conjugated nanoparticles or TRA-1-60-
conjugated nanoparticles. The SERS signal intensity detected by
both SSEA-5- and TRA-1-60-SERS assays was positively correlated
with the number of stem cells (Fig. 5A). For samples containing1%
stem cells, the SERS signal intensity displayed linear correlation
with the number of hPSCs (R2 ¼ 0.98e0.99, Fig. 5A, insets). The
limit of detection (LOD) was 0.0001% SSEA-5þ or 0.0001% TRA-1-
60þ stem cells (i.e. 1 stem cell in a background of 106 cells). In
Fig. 5. Sensitivity of SSEA-5-conjugated and TRA-1-60-conjugated nanoparticles for the detection of hPSCs. (A) Correlation between the relative SERS intensity from SSEA-5-
conjugated nanoparticles or TRA-1-60-conjugated nanoparticles and the amount of stem cells in mixed cell preparations of hPSCs and NIH3T3 ﬁbroblasts. SERS signals from
nanoparticles bounded with cells were recorded and plotted against the concentration of stem cells. The horizontal line indicates the SERS intensity value that equals to the mean
plus 3 standard deviations of the measurements of NIH3T3 cells. The LOD was determined as the concentration of stem cells at the intersection between the horizontal line and the
standard curve. (B) Correlation between the percentage of SSEA-5þ or TRA-1-60þ cells detected by ﬂow cytometry and the amount of stem cells in mixed cell preparations of hPSCs
and NIH3T3 ﬁbroblasts. The horizontal line indicates the value that equals to the mean plus 3 standard deviations of the measurements of NIH3T3 cells by ﬂow cytometry.
J. Han et al. / Biomaterials 105 (2016) 66e7672contrast, the estimated LOD for ﬂow cytometry analysis was 0.2%
SSEA-5þ or 1.5% TRA-1-60þ stem cells (i.e. 2000 or 15,000 stem
cells in a background of 106 cells) (Fig. 5B). Therefore, the sensitivity
of the SERS assays was ~2000 to 15,000-fold higher than that of
ﬂow cytometry assays.
3.3. Development of a multiplexing SERS assay: speciﬁcity and
sensitivity
We also examined whether SSEA-5þ and TRA-1-60þ cells could
be detected simultaneously in a multiplexing assay using nano-
particles with distinct SERS spectral patterns. SSEA-5 antibodies
were conjugated with Au nanoparticles labelled with the BIDI re-
porter and TRA-1-60 antibodies with Au nanoparticles labelled
with the black hole quencher dye (BHQ) reporter. These nano-
particles emitted SERS signals at the spectral region of
200e1800 cm1 when they were simultaneously excited with a
single laser bean at 785 nm [21] (Fig. 6A). After stem cells were
labelled with these nanoparticles, the ﬁnal SERS spectra detected in
the multiplexing assay was a combination of two distinct SERS
spectral patterns (Fig. 6A). Signals from SSEA-5-conjugated and
TRA-1-60-conjugated nanoparticles were distinguished using their
unique SERS signals at different spectral regions (marked in pink
and blue, respectively, Fig. 6A).
We then assessed the speciﬁcity and sensitivity of these SSEA-5-
conjugated and TRA-1-60-conjugated nanoparticles in themultiplexing assay. Similar to the SERS assays for single surface
markers, the multiplexing assay detected strong SERS signals from
SSEA-5-conjugated and TRA-1-60-conjugated nanoparticles in
IMR-90 iPSCs and H7 hESCs (Fig. 6B), but only negligible SERS
signals in cardiomyocytes and ﬁbroblasts (Fig. 6B), suggesting
speciﬁc bindings of SSEA-5-conjugated and TRA-1-60-conjugated
nanoparticles to stem cells. When these nanoparticles were used
to detect SSEA-5þ and TRA-1-60þ cells in mixed cell preparations
containing varying numbers of stem cells, the SERS signal intensity
detected by both SSEA-5-conjugated and TRA-1-60-conjugated
nanoparticles was positively correlated with the number of stem
cells (R2 ¼ 0.98) with LOD estimated at 0.0006% for SSEA-5þ cells
and 0.0004% for TRA-1-60þ cells (Fig. 6C and D).
3.4. Detection of SSEA-5þand TRA-1-60þ cells in cardiomyocyte
differentiation cultures
We next applied the multiplexing SERS assays to analyze re-
sidual SSEA-5þ and TRA-1-60þ cells in cardiomyocyte differentia-
tion cultures. We previously reported that the formation of 3D
cardiac spheres using a microscale, forced aggregation technology
efﬁciently enriched hPSC-derived cardiomyocytes, possibly
through homophilic association of cardiomyocytes during sphere
formation [28]. We speculated that the 3D sphere culture method
could also reduce the number of residual SSEA-5þ and TRA-1-60þ
cells. To test this hypothesis, we induced cardiomyocyte
Fig. 6. Speciﬁcity and sensitivity of multiplexing SSEA-5-conjugated and TRA-1-60-conjugated nanoparticles for the detection of hPSCs. (A) Principle of the multiplexing SERS assay.
SSEA-5-conjugated and TRA-1-60-conjugated nanoparticles with distinct SERS spectrum patterns were applied to the same cell preparation. SERS signals from these nanoparticles
were detected simultaneously and distinguished by their unique SERS signals at speciﬁc spectral regions (pink: SSEA-5-conjugated nanoparticles; blue: TRA-1-60-conjugated
nanoparticles). (B) Speciﬁcity of the multiplexing SERS assay. SERS signals were detected in IMR-90 iPSCs (red) and H7 hESCs (black) but not in primary rat cardiomyocytes
(CM, blue) or NIH3T3 ﬁbroblasts (3T3, green). (C) SERS spectra obtained from cell preparations containing various numbers of stem cells. (D) Sensitivity of the multiplexing SERS
assay. Linear standard curves for SERS signals from the nanoparticles were plotted against the concentration of stem cells. The horizontal line indicates the SERS intensity value that
equals to the mean plus 3 standard deviations of the measurements of NIH3T3 cells. The LOD was determined as the concentration of stem cells at the intersection between the
horizontal line and the standard curve. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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spheres at differentiation day 4 (Fig. 7A). After 24 h, the cells
formed 3D spheres which were then transferred to suspension
culture and maintained until differentiation day 17, while the par-
allel 2D cultures remained as densely packed adherent cells
(Fig. 7B). In both 2D and 3D cultures, beating cells were detected
ﬁrst at day 10 and continued to beat until harvesting. At day 17,
cardiomyocyte purity was higher in 3D cultures (94 ± 2%) than 2D
cultures (48 ± 29%) as detected by ﬂow cytometry analysis of a-
actinin, a cardiomyocyte-associated marker (Fig. 7C and D). We
then assessed the amount of residual SSEA-5þ or TRA-1-60þ cells in
2D and 3D cultures. Using themultiplexing SERS assay, we detected
4.64e5.18% SSEA-5þ and 5.77e9.44% TRA-1-60þ cells for 2D cul-
ture, but only 0.009e1.15% SSEA-5þ and 0.008e0.665% TRA-1-60þ
cells were detected in 3D cultures (Fig. 7E). These results suggest
that 3D sphere culture reduced residual SSEA-5þ and TRA-1-60þ
cells and that the SERS assay can be used to detect the residual
SSEA-5þ and TRA-1-60þ cells in cardiomyocyte differentiation
cultures.
4. Discussion
In this study, we developed nanoparticles targeting two stemcell surface markers, SSEA-5 and TRA-1-60. These assays demon-
strated high speciﬁcity for hPSCs, and their sensitivity was several
orders of magnitude higher than that of ﬂow cytometry assays
(0.0001%e0.0006% vs. ~0.2%e1.5%). The sensitivity of these SERS
assays is 10-fold higher than what is expected for a quality-control
assay for stem cell products. Using the SERS assay, we found that 3D
sphere cardiomyocyte differentiation cultures had reduced
numbers of residual SSEA-5þ and TRA-1-60þ cells compared to the
parallel 2D cultures.
Compared with current detection technologies for residual stem
cells such as ﬂow cytometry and teratoma testing, the SERS assays
we have developed have several attributes that are highly desired
for the quality-control of hPSC-derived products. Because of their
remarkable sensitivity, these SERS assays may facilitate safety
assessment of cell preparations for transplantations that require a
large quantity of cells, which is unachievable using ﬂow cytometry
or the teratoma assay in mice. In addition, these assays are cost-
effective, easy to use, and can be done within an hour, which is
much faster than the traditional teratoma assay.
Successfully establishing SERS assays with ultra-high sensitivity
requires ﬁne tuning several elements during the preparation of
nanoparticles and overall assay design. As exempliﬁed in this study,
the PEG layer and ligand density could signiﬁcantly affect the
Fig. 7. Detection of residual SSEA-5þ and TRA-1-60þ cells in CM differentiation cultures. (A) Experimental design. Cardiomyocyte differentiation was induced by the treatment of
activin A and BMP4. At differentiation day 4, cells were dissociated and forced to form 3D spheres using a microscale technology. After 24 h, the spheres were transferred and
maintained in suspension culture. At differentiation day 17, both 3D cells and the parallel 2D cultures were harvested and analyzed for cardiomyocyte purity and levels of residual
SSEA-5þ and TRA-1-60þ cells. (B) Cell morphology of 2D and 3D cultures. Scale bar ¼ 100 mm. (C) Representative ﬂow cytometry analysis of a-actinin, a cardiomyocyte-associated
marker. (D) Summary of cardiomyocyte purity determined by ﬂow cytometry analysis of a-actinin. (E) Levels of residual SSEA-5þ and TRA-1-60þ cells in 2D and 3D cardiomyocyte
differentiation cultures. Test samples from differentiation cultures and standard samples (cell preparations containing various amounts of hPSCs mixed with NIH3T3 ﬁbroblasts)
were analyzed by the multiplexing SERS assay. Levels of residual SSEA-5þ and TRA-1-60þ cells in the test samples were determined according to standard curves.
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established in this study was 10- to 50-fold higher than the SERS
assay we developed previously for detecting circulating tumor cells
[27]. Although this could be contributed by many factors, including
differences in target cell types, background cells, targeting ligands,
and the afﬁnity of ligand binding, the increased SERS assay sensi-
tivity was likely resulted from our recent improvement in SERS
assay development. In nanoparticle designs, PEG coatings are used
to protect the Raman reporter from the biological environment and
keep the reporter locked to the nanoparticle surface in order to
preserve SERS intensities and stability [20,21]. Notably, we
demonstrated that a PEG-SH with higher molecular weight was
optimal for TRA-1-60 (IgM)-conjugated nanoparticles; the nano-
particles with PEG20K had 26-fold increased relative SERS signals
compared with those with PEG5K.The SERS assays we developed in this study enable labeling and
detection of a trace number of cells that express stem cell markers
either SSEA-5 or TRA-1-60 pluripotency markers. SSEA-5 is a
recently-identiﬁed antigen which is highly and speciﬁcally
expressed on hPSCs [31]. Immunodepletionwith antibodies against
SSEA-5 greatly reduced the potential of teratoma formation from
partially differentiated cultures [31]. TRA-1-60 is another surface
marker characteristic of undifferentiated hPSCs, and antibodies
against TRA-1-60 can also detect undifferentiated stem cells from
heterogeneous cell population [11,33]. It is possible that monitoring
multiple markers is required in order to assure the safety of hPSC-
derived products, since tumor formation from these cell products
can be more complex than anticipated. In general, tumors can be
derived from residual undifferentiated cells, but hypothetically may
also be caused by malignant transformation of differentiated or
J. Han et al. / Biomaterials 105 (2016) 66e76 75partially differentiated cells [3]. Correspondingly, the strategy to
increase safety is to assure the absence of undifferentiated cells or
other partially differentiated cell that could initiate tumor forma-
tion [3], and developmethods to selectively eliminate residual stem
cells [34e40]. It was reported that qRT-PCR analysis of LIN28 can
detect residual undifferentiated hPSCs with a high sensitivity,
although other stem cell markers including OCT3/4 and NANOG are
not suitable for PCR-based assays to detect lowamount of stem cells
in a mixed population [11]. With the anticipation that measure-
ments of multiple markers are needed to accurately predict the
tumorigenic potential of hPSC-derived products, the SERS assays
and PCR method may be used together, given that the technologies
detect different molecular characteristics (i.e. the SERS assays
detect proteins, glycoproteins, and other epitopes, while the PCR
method detects mRNA). In conjunction with other methods, SERS
technology will enable the development of assays targeting a
multitude of markers characteristic of pluripotent cells or their
early differentiated progeny with tumorigenic potential. Assays
such as these should be applicable for the detection of stem cells in
differentiation cultures of other lineages such as neural, endo-
dermal, or hematopoietic cells.
5. Conclusion
Development of a rapid, economic, and accurate assay for the
detection of undifferentiated stem cells is highly desirable to meet
the expanding demand for stem cells in clinical applications, where
safety concerns due to tumorigenic potential of undifferentiated
stem cells are a critical issue. Here, we have developed highly
sensitive SERS assays based on a comprehensively-engineered
nanoparticle design to speciﬁcally detect trace numbers of SSEA-
5þ and TRA-1-60þ stem cells. These assays are able to identify as
few as 1 stem cell out of 1 million differentiated cells, a sensitivity
(0.0001%) that is 3e4 orders of magnitude better than ﬂow
cytometry assays and 10-fold higher than the requirement for pu-
tative quality-control assays. Using the multiplexing SERS assay, we
also demonstrated that the formation of 3D spheres from hPSC-
based cardiomyocyte differentiation cultures signiﬁcantly reduces
the number of residual stem cells compared with parallel 2D cul-
tures. Given their speed and cost-effectiveness, these assays could
facilitate the accurate and efﬁcient assessment of hPSC-based
products for pre-clinical and clinical applications by addressing
safety concerns that are common to all stem cell-based therapies.
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